Pharma: Page 38
-
David Dee Delgado via Getty Images
Pfizer buys sickle cell drugmaker Global Blood for $5.4B
The acquisition gives Pfizer access to Oxbryta, an approved drug for the blood condition, as well as two experimental medicines.
By Delilah Alvarado , Ned Pagliarulo • Updated Aug. 8, 2022 -
Permission granted by Gilead Sciences
How a small UK biotech ended up in Gilead’s hands
MiroBio, which was spun out of the University of Oxford three years ago, drew Gilead’s interest with its autoimmune disease research.
By Gwendolyn Wu • Aug. 5, 2022 -
Explore the Trendline➔
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
TrendlineAlzheimer's disease
Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.
By BioPharma Dive staff -
Novo shares tumble after latest setbacks for closely watched obesity drug
The Danish drugmaker lost tens of billions in market value after revealing a key clinical study for Wegovy won't be stopped early and production issues are still being ironed out.
By Kristin Jensen • Aug. 4, 2022 -
iStock via Getty Images
With new data, Roche takes step toward more convenient cancer immunotherapy
The pharma claimed Phase 3 study success for a subcutaneous version of its drug Tecentriq, a strategy it and rivals Merck and Bristol Myers could use to extend the market life of their lucrative drugs.
By Ben Fidler • Aug. 2, 2022 -
Getty Images
Sponsored by Avanir PharmaceuticalsThe cost of purpose: Finding personal fulfillment in a pharmaceutical career
Wa’el Hashad, President and CEO of Avanir Pharmaceuticals, discusses purpose and fulfillment in a pharmaceutical career.
By Wa’el Hashad, President and CEO, Avanir Pharmaceuticals • Aug. 1, 2022 -
Lisa Maree Williams via Getty Images
AbbVie cancer drug sales fall as AstraZeneca competitor gains ground
Imbruvica, long one of AbbVie’s top-selling medicines, has ceded market share in treating chronic lymphocytic leukemia to AstraZeneca’s Calquence.
By Ned Pagliarulo • July 29, 2022 -
Dan Kitwood via Getty Images
Pfizer sales of COVID-19 vaccine, pill beat forecasts as company prepares for future waves
The company plans to ready a booster shot by the fall that targets the BA.4 and BA.5 strains that are currently most prevalent in the U.S. and other countries.
By Christopher Newman • Updated July 28, 2022 -
Novartis asks FDA to approve biosimilar for Biogen’s top-selling MS drug
Biogen will try to enforce patents protecting Tysabri, but an executive last week acknowledged that copycat drugs could launch when approved in the U.S.
By Jonathan Gardner • July 25, 2022 -
Sean Gallup via Getty Images
EU speeds approval of monkeypox vaccine as WHO declares public health emergency
Vaccine maker Bavarian Nordic said it is meeting demand for its shot with production capacity of 30 million doses a year.
By Christopher Newman • July 25, 2022 -
Carl Court via Getty Images
European regulator recommends Bavarian Nordic's vaccine for monkeypox
The positive decision comes as governments aim to expand supply and quicken distribution of the vaccine to combat a widening global outbreak. Separately, the EMA backed approvals of 11 other medicines.
By Christopher Newman • July 22, 2022 -
Courtesy of Roche
Roche CEO Schwan, who guided company as cancer drug powerhouse, to step down next year
The drugmaker’s current diagnostics chief Thomas Schinecker will take over as CEO in March, while Schwan will seek election as chair of Roche’s board.
By Jonathan Gardner • July 21, 2022 -
Getty Images
Roche digs deeper into gene therapy for the eye
The Swiss drugmaker, which already owns rights to a marketed gene therapy for inherited vision loss, will work with startup Avista Therapeutics to develop better delivery tools for the complex treatments.
By Jonathan Gardner • July 20, 2022 -
Jacob Bell/BioPharma Dive
Merck terminates Lynparza trial in colorectal cancer
The setback slows plans to broaden use of a drug that analysts expect to generate nearly $10 billion in annual sales later this decade.
By Jonathan Gardner • July 19, 2022 -
Permission granted by Novartis
Novartis forecasts improving generic drug business as it weighs unit's future
The pharmaceutical company is considering selling or splitting off its struggling Sandoz division and expects to give an update by the end of the year.
By Ned Pagliarulo • July 19, 2022 -
Brian Tucker/BioPharma Dive
Drug deals, launches in focus as pharma earnings begin
Second quarter reports could bring questions on a reportedly forthcoming $40 billion takeover, GSK’s new slimmed-down look and market uptake for expected blockbusters from Lilly and Bristol Myers.
By Ned Pagliarulo , Jonathan Gardner • July 18, 2022 -
Carsten Koall via Getty Images
EMA adds allergic reaction warning to Novavax's COVID-19 vaccine
The regulator said there have been “a few” spontaneous severe allergic reactions following administration of the vaccine, which was this week authorized in the U.S.
By Christopher Newman • July 15, 2022 -
Sarah Silbiger via Getty Images
Novartis, BeiGene cancer drug faces delay as FDA puts off approval decision
The deferral puts the drug in regulatory limbo, setting back the Swiss pharma's efforts to catch up to top immunotherapy developers Merck, Bristol Myers Squibb and Roche.
By Ned Pagliarulo • July 14, 2022 -
Carsten Koall via Getty Images
FDA clears Novavax’s COVID-19 vaccine as 4th option in US
The shot is the first of its type authorized for COVID-19 by the FDA, but faces an uncertain future due to questions about its ability to fight omicron as well as the biotech’s ability to manufacture large quantities.
By Jonathan Gardner • Updated July 13, 2022 -
Erik S. Lesser via Getty Images
Merck wagers $290M on a cancer treatment from Finnish drugmaker
The treatment, developed by Orion Corporation, is in Phase 2 testing for advanced prostate cancer, and adds to Merck’s oncology pipeline
By Kristin Jensen • July 13, 2022 -
Getty Images
Healthcare asset manager Innoviva buys another biotech at a bargain price
Two months after acquiring Entasis Therapeutics, the firm reached a deal to buy La Jolla Pharmaceutical Co. at a fraction of what La Jolla was worth just a few years ago.
By Jonathan Gardner • July 11, 2022 -
Getty Images
Sponsored by Worldwide Clinical TrialsDe-risking oncology trials with medical monitoring
Phase three oncology studies have approximately a 35% likelihood of leading to regulatory approval.
July 11, 2022 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
AbbVie dials back partnership on experimental Alzheimer's drug
While AbbVie is bailing on one of the two programs it paid Alector $205 million to acquire five years ago, work will continue on the second project. That drug, however, has shown safety signals.
By Jonathan Gardner • July 8, 2022 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
FDA, under fire for Aduhelm approval, starts review of another Alzheimer's drug
The regulator could clear Biogen and Eisai’s lecanemab by early January. A decision before Phase 3 results could amplify the criticism the agency already faces, however.
By Jonathan Gardner • July 6, 2022 -
Antonio Masiello via Getty Images
US pays Pfizer $3.2B to increase vaccine supply ahead of omicron booster push
The order will bolster the government stockpile of COVID-19 vaccines ahead of a booster rollout that the FDA now says should include shots tailored to the newest versions of omicron.
By Kristin Jensen • June 30, 2022 -
Courtesy of Sanofi
FDA halts tests of Sanofi drug, acquired in $3.7B buyout, due to side effects
Liver problems in trial volunteers led the agency to curtail studies of the drug, marking the second major setback related to Sanofi’s acquisition of Principia Biopharma.
By Jonathan Gardner • June 30, 2022
Previous
